• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP:RVVTF)

0.0140 +0.0003 (+2.19%)
Delayed Quote Updated: 10:09 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,707
Open 0.0140
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0137
Today's Range 0.0140 - 0.0140
52wk Range 0.0021 - 0.0585
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
September 15, 2026
Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs 
From Revive Therapeutics Ltd.
Via ACCESS Newswire
News headline image
Revive Therapeutics Announces Proposed Shares for Debt Settlement
August 19, 2026
From Revive Therapeutics Ltd.
Via ACCESS Newswire

Performance

52-Week Range 76.1% below 52-week high
0.0140
0.0052W Low 0.0652W High
1 Week 24.3% below 1-week high
0.011W Low 0.021W High

Revive Therapeutics Ltd (RVVTF) traded between $0.00 and $0.06 over the past 52 weeks and last traded at $0.01, 76.1% below its 52-week high. Over the past week it ranged between $0.01 and $0.02.

Past 12 Months
-11.9%
-28.6%
-20.9%
-37.8%
+52.2%
+48.9%
1W -$0.00
1M -$0.01
3M -$0.00
6M -$0.01
YTD +$0.00
1Y +$0.00

RVVTF was +48.9% over the past year, -37.8% over six months, +52.2% year to date, -11.9% in the last week.

12 Months vs Market
RVVTF
+48.9%
DIA
+12.6%
SPY
+12.2%
QQQ
+9.5%
IWM
+15.7%

Over the past 12 months RVVTF returned +48.9% versus DIA (Dow) +12.6%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +9.5% and IWM (Russell 2000) +15.7%.

Volume & Liquidity 0.01× 3-mo avg
Today 1,707 3-mo avg 166.4K
1W
148.6K
1M
90.9K
3M
166.4K
6M
177.7K
YTD
313.0K
1Y
326.3K

RVVTF most recently traded 1,707 shares against a 3-month average daily volume of 166.4K.

More News

Read More
News headline image
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
August 19, 2026
From Revive Therapeutics Ltd.
Via ACCESS Newswire
News headline image
Revive Therapeutics Reports Grant of Options
August 14, 2026
From Revive Therapeutics Ltd.
Via ACCESS Newswire
News headline image
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
May 20, 2026
Via ACCESS Newswire
News headline image
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
March 11, 2026
Via ACCESS Newswire
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
December 15, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
November 21, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
September 19, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Extension of Proposed Private Placement
September 05, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
August 11, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
July 30, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
July 08, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
June 26, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Advances with Next-Generation Bucillamine Development
June 04, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
May 12, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Shares for Debt Transaction
April 21, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
April 10, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
April 01, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Results of Annual Shareholder Meeting
March 19, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
March 03, 2025
Via Newsfile
News headline image
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
March 03, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
February 03, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
January 08, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
November 12, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Revive Therapeutics Ltd publicly traded?
Yes, Revive Therapeutics Ltd is publicly traded.
What exchange does Revive Therapeutics Ltd trade on?
Revive Therapeutics Ltd trades on the OTC Traded
What is the ticker symbol for Revive Therapeutics Ltd?
The ticker symbol for Revive Therapeutics Ltd is RVVTF on the OTC Traded
What is the current price of Revive Therapeutics Ltd?
The current price of Revive Therapeutics Ltd is 0.0140
When was Revive Therapeutics Ltd last traded?
The last trade of Revive Therapeutics Ltd was at 11/04/26 10:09 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap